SCHEMBL6571628

SCHEMBL6571628

O=C(NN=Cc1ccc(O)c(O)c1O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.74
KMT2A Q03164 4/20 0.74
LMNA P02545 3/20 0.74
PTBP1 P26599 2/20 0.74
HTT P42858 2/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
POLB P06746 2/20 0.74
TDP1 Q9NUW8 1/20 0.74
MAPT P10636 6/20 0.65
MEN1 O00255 3/20 0.65
GAA P10253 2/20 0.63
HPGD P15428 2/20 0.63
HSP90AA1 P07900 1/20 0.63
ALOX12 P18054 1/20 0.63
ALDH1A1 P00352 1/20 0.60
MPI P34949 1/20 0.60
RECQL P46063 1/20 0.60
MCL1 Q07820 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
NTRK1 P04629 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6571625 1.00 KDM4E (0.74) KDM4EKMT2ALMNAPTBP1HTT
SCHEMBL6747942 0.89 MAPT (0.61) KDM4EKMT2ALMNAPTBP1HTT
SCHEMBL6571385 0.89 MAPT (0.61) KDM4EKMT2ALMNAPTBP1HTT
SCHEMBL6571440 0.86 KDM4E (0.78) KDM4EKMT2ALMNAPTBP1HTT
SCHEMBL6568354 0.86 KMT2A (0.78) KDM4EKMT2ALMNAPTBP1HTT
SCHEMBL6571437 0.86 KDM4E (0.78) KDM4EKMT2ALMNAPTBP1HTT
SCHEMBL6568357 0.86 KMT2A (0.78) KDM4EKMT2ALMNAPTBP1HTT
SCHEMBL684556 0.85 KMT2A (1.00) KDM4EKMT2ALMNAPTBP1HTT
SCHEMBL6571712 0.85 KMT2A (1.00) KDM4EKMT2ALMNAPTBP1HTT
SCHEMBL6749902 0.85 KDM4E (0.78) KDM4EKMT2ALMNAPTBP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KDM4E 3228/4885KMT2A 3368/4885LMNA 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.